The first line and second line antiretroviral therapy (ART) is given to HIV/AIDS patients free of cost in all ART Centres across the country presently. The Technical Resource Group on ART on 27th December, 2013 recommended providing third line antiretroviral therapy for HIV/AIDS patients through 10 centres of excellence across the country. The process for … Read more
The Union Health and Family Welfare Minister, Shri Ghulam Nabi Azad launched the National AIDS Control Programme Phase IV (NACP IV). NACP-IV aims to accelerate the process of epidemic reversal and further strengthen the epidemic response in India through a cautious and well defined integration process over the five-year period, 2012- 2017. It consolidates the … Read more
When a host cell is infected with HIV, the virus brings its own genetic material into the host cell. This cell then replicates, reads the viral RNA, and uses it as a blueprint to produce more viral proteins. Complete viruses are then released to attack the next cells.
Despite the availability of life-saving antiretroviral treatment, people infected with HIV (human immunodeficiency virus) continue to die and suffer from complications of AIDS, mainly due to delayed diagnosis and initiation of treatment. A researcher at the Albert Einstein College of Medicine of Yeshiva University and colleagues at Yale University have shed light on why this problem persists. They report their findings in the November issue of the journal Medical Care.
The largely unnoticed collision of the global epidemics of HIV and tuberculosis (TB) has exploded to create a deadly co-epidemic that is rapidly spreading in sub-Saharan Africa. However, health systems cannot adequately diagnose, treat, or contain the co-epidemic due to unanswered scientific and medical questions, according to a report issued today by The Forum for Collaborative HIV Research and amplified by experts from leading global health organizations.
It was hoped that as HIV treatment improved and as HIV-related public health initiatives encouraged people to be tested for the disease and seek care, that HIV-infected patients would seek care quickly. Unfortunately, a new study indicates that patients are actually sicker when they begin therapy. The study is published in the November 15 issue of Clinical Infectious Diseases, currently available online.
The United Nations refugee agency has launched a new project to boost HIV and AIDS services among the conflict-affected populations in Nepal.
Helicobacter pylori has been extensively studied and proven to be the main cause of chronic gastritis and peptic ulcer in the HIV-negative population. Patients with chronic active gastritis have evidence of H pylori infection in over 90% of cases and in 70-100% of those with peptic ulcer disease. However, the reason for low incidence of H pylori infection in HIV-positive patients was still not very clear.
For African Americans infected with HIV, the risk of end-stage renal disease is six times higher than for whites with HIV — and similar to the ESRD risk associated with diabetes, reports a study in the November Journal of the American Society of Nephrology.
The U.S. Food and Drug Administration (FDA) has approved raltegravir tablets for treatment of Human Immunodeficiency Virus (HIV)-1 infection in combination with other antiretroviral agents in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents.